Two years survival of primary cardiac leiomyosarcoma managed by surgical and adjuvant therapy.

Clinical Sarcoma Research Pub Date : 2017-03-09 eCollection Date: 2017-01-01 DOI:10.1186/s13569-017-0069-3

K Behi, M Ayadi, E Mezni, K Meddeb, A Mokrani, Y Yahyaoui, F Ksontini, H Rais, N Chrait, A Mezlini

引用次数: 7

Abstract

Background: Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases.

Case presentation: a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local or distant recurrence.

Conclusions: Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. Adjuvant treatment is still controversial.

Abstract Image

查看原文本刊更多论文

通过手术和辅助治疗的原发性心脏平滑肌肉瘤的2年生存率。

背景:心脏肿瘤是一种非常罕见的肿瘤。平滑肌肉瘤占不到1%的病例。病例介绍:一名51岁女性，诊断为原发性左心房平滑肌肉瘤。她接受了最佳手术和辅助化疗。随访24个月后，患者仍然存活，无局部或远处复发的迹象。结论:心脏平滑肌肉瘤是一种罕见的肿瘤，预后较差。手术是治疗的主要手段。辅助治疗仍有争议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Sarcoma Research

自引率

0.00%

发文量

期刊介绍： Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.